Aemetis, Inc (NASDAQ:AMTX) has received a consensus broker rating score of 3.00 (Hold) from the one analysts that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation.

Brokers have set a 12 month consensus target price of $2.00 for the company and are anticipating that the company will post ($0.24) EPS for the current quarter, according to Zacks. Zacks has also assigned Aemetis an industry rank of 66 out of 265 based on the ratings given to related companies.

A number of research firms have issued reports on AMTX. B. Riley reissued a “hold” rating and set a $2.00 target price on shares of Aemetis in a research report on Monday, November 13th. Zacks Investment Research upgraded Aemetis from a “sell” rating to a “hold” rating in a research note on Tuesday, October 17th. Finally, FBR & Co restated a “neutral” rating and set a $2.00 price target on shares of Aemetis in a research note on Saturday, August 19th.

Aemetis (AMTX) traded up $0.04 during midday trading on Wednesday, hitting $0.72. The stock had a trading volume of 21,100 shares, compared to its average volume of 49,566. The company has a debt-to-equity ratio of -1.87, a current ratio of 0.37 and a quick ratio of 0.20. Aemetis has a fifty-two week low of $0.53 and a fifty-two week high of $2.50.

A hedge fund recently bought a new stake in Aemetis stock. Ninepoint Partners LP acquired a new stake in Aemetis, Inc (NASDAQ:AMTX) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 1,151,373 shares of the specialty chemicals company’s stock, valued at approximately $1,002,000. Ninepoint Partners LP owned 5.81% of Aemetis as of its most recent SEC filing. 25.67% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Zacks: Aemetis, Inc (AMTX) Receives Consensus Rating of “Hold” from Analysts” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was copied illegally and republished in violation of US & international copyright & trademark law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/06/zacks-aemetis-inc-amtx-receives-consensus-rating-of-hold-from-analysts.html.

About Aemetis

Aemetis, Inc is an international renewable fuels and biochemicals company. The Company is focused on the production of fuels and chemicals through the acquisition, development and commercialization of technologies that replace traditional petroleum-based products by conversion of first-generation ethanol and biodiesel plants into biorefineries.

Get a free copy of the Zacks research report on Aemetis (AMTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aemetis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aemetis Inc and related companies with MarketBeat.com's FREE daily email newsletter.